Literature DB >> 25633415

Activation of peroxisome proliferator-activated receptor γ (PPARγ) through NF-κB/Brg1 and TGF-β1 pathways attenuates cardiac remodeling in pressure-overloaded rat hearts.

Han-Ping Qi1, Ye Wang, Qian-Hui Zhang, Jing Guo, Lei Li, Yong-Gang Cao, Shu-Zhi Li, Xiao-Lei Li, Mu-Mu Shi, Wang Xu, Bai-Yan Li, Hong-Li Sun.   

Abstract

BACKGROUND/AIMS: Cardiac remodeling is a common pathophysiological change along with chronic hypertension and myocardial infarction. Recent evidence indicated that cardiac tissue expressed peroxisome proliferator-activated receptor γ (PPARγ). However, the functional role of PPARγ in cardiac remodeling remained unclear. The present study was designed to investigate the relationship between PPARγ activation and pressure overload-induced cardiac remodeling.
METHODS: Cardiac remodeling model was successfully established by abdominal aorta ligation. Cardiac fibrosis and cardiomyocyte hypertrophy were simulated by 100 nM angiotensin II (Ang II) in vitro. Haemodynamic parameters, the expressions of Brg1, α-MHC, β-MHC, transforming growth factor beta 1 (TGF-β1), collagen-I, collagen-III and NF-κB were examined.
RESULTS: Morphological and haemodynamic measurements showed that the activation of PPARγ improved the impaired cardiac function and decreased interstitial fibrosis in cardiac remodeling rats. Further results also showed that the activation of PPARγ inhibited the expressions of Brg1 and TGF-β1 in the cardiac remodeling hearts. The activation of PPARγ also inhibited the proliferation and collagen production of cardiac fibroblasts, and down-regulated the activity of Brg1 and the expression of TGF-β1 induced by Ang II in cultured neonatal rat cardiomyocytes and cardiac fibroblasts, respectively, through NF-κB pathway.
CONCLUSIONS: These results suggested that PPARγ activation effectively inhibited cardiac remodeling processes by suppression of Brg1 and TGF-β1 expressions through NF-κB pathway in the pressure-overloaded hearts induced by abdominal aorta ligation in rats.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633415     DOI: 10.1159/000369747

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  24 in total

1.  Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.

Authors:  Jie Luo; Bin Chen; Xian-Xiu Ji; Song-Wen Zhou; Di Zheng
Journal:  Tumour Biol       Date:  2015-08-28

2.  Peroxisome proliferator-activated receptor γ (PPARγ) mediates the protective effect of quercetin against myocardial ischemia-reperfusion injury via suppressing the NF-κB pathway.

Authors:  Xinyu Liu; Zhangjie Yu; Xian Huang; Yi Gao; Xiuzhi Wang; Jianmin Gu; Song Xue
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  Transient receptor potential vanilloid-3 (TRPV3) activation plays a central role in cardiac fibrosis induced by pressure overload in rats via TGF-β1 pathway.

Authors:  Yan Liu; Hanping Qi; Mingyao E; Pilong Shi; Qianhui Zhang; Shuzhi Li; Ye Wang; Yonggang Cao; Yunping Chen; Lina Ba; Jingquan Gao; Wei Huang; Hongli Sun
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-16       Impact factor: 3.000

Review 4.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

5.  Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy.

Authors:  Chun-Mei Tang; Fang-Zhou Liu; Jie-Ning Zhu; Yong-Heng Fu; Qiu-Xiong Lin; Chun-Yu Deng; Zhi-Qin Hu; Hui Yang; Xi-Long Zheng; Jian-Ding Cheng; Shu-Lin Wu; Zhi-Xin Shan
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

6.  Activation of AMPK Attenuated Cardiac Fibrosis by Inhibiting CDK2 via p21/p27 and miR-29 Family Pathways in Rats.

Authors:  Hanping Qi; Yan Liu; Shuzhi Li; Yunping Chen; Lei Li; Yonggang Cao; Mingyao E; Pilong Shi; Chao Song; Baiyan Li; Hongli Sun
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-08       Impact factor: 8.886

Review 7.  Novel Anti-fibrotic Therapies.

Authors:  Benita L McVicker; Robert G Bennett
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

Review 8.  Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis.

Authors:  Huang-Jun Liu; Hai-Han Liao; Zheng Yang; Qi-Zhu Tang
Journal:  PPAR Res       Date:  2016-05-12       Impact factor: 4.964

9.  Targeting myocyte-specific enhancer factor 2D contributes to the suppression of cardiac hypertrophic growth by miR-92b-3p in mice.

Authors:  Zhi-Qin Hu; Jian-Fang Luo; Xue-Ju Yu; Jie-Ning Zhu; Lei Huang; Jing Yang; Yong-Heng Fu; Tao Li; Yu-Mei Xue; Ying-Qing Feng; Zhi-Xin Shan
Journal:  Oncotarget       Date:  2017-09-08

10.  Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts.

Authors:  Wen-Si Zhu; Chun-Mei Tang; Zhen Xiao; Jie-Ning Zhu; Qiu-Xiong Lin; Yong-Heng Fu; Zhi-Qin Hu; Zhuo Zhang; Min Yang; Xi-Long Zheng; Shu-Lin Wu; Zhi-Xin Shan
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.